ID   YD-9
AC   CVCL_L080
SY   YD9
DR   IARC_TP53; 21617
DR   KCLB; 60502
DR   Wikidata; Q54995394
RX   PubMed=16264262;
RX   PubMed=28053903;
CC   Population: Korean.
CC   Doubling time: 33.4 hours (PubMed=16264262).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=16264262).
CC   Derived from site: In situ; Oral cavity, buccal mucosa; UBERON=UBERON_0006956.
ST   Source(s): KCLB=60502; PubMed=16264262
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 13
ST   D16S539: 12,13
ST   D18S51: 13
ST   D21S11: 30
ST   D3S1358: 15,16
ST   D5S818: 10,12
ST   D7S820: 11,12
ST   D8S1179: 11,13
ST   FGA: 25
ST   Penta D: 9
ST   Penta E: 15,17
ST   TH01: 6
ST   TPOX: 8,9
ST   vWA: 14,19
DI   NCIt; C4040; Buccal mucosa squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 19-12-24; Version: 19
//
RX   PubMed=16264262; DOI=10.1038/emm.2005.48;
RA   Lee E.J., Kim J., Lee S.A., Kim E.-J., Chun Y.-C., Ryu M.H.,
RA   Yook J.-I.;
RT   "Characterization of newly established oral cancer cell lines derived
RT   from six squamous cell carcinoma and two mucoepidermoid carcinoma
RT   cells.";
RL   Exp. Mol. Med. 37:379-390(2005).
//
RX   PubMed=28053903; DOI=10.5125/jkaoms.2016.42.6.337; PMCID=PMC5206238;
RA   Jo D.-W., Kim Y.-K., Yun P.-Y.;
RT   "The influence of p53 mutation status on the anti-cancer effect of
RT   cisplatin in oral squamous cell carcinoma cell lines.";
RL   J. Korean Assoc. Oral Maxillofac. Surg. 42:337-344(2016).
//